ChromaDex Co. (NASDAQ:CDXC – Get Rating)’s stock price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.63 and traded as high as $1.91. ChromaDex shares last traded at $1.90, with a volume of 78,946 shares traded.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on CDXC. StockNews.com raised shares of ChromaDex from a “hold” rating to a “buy” rating in a report on Friday, November 4th. B. Riley reduced their price objective on shares of ChromaDex from $2.40 to $2.10 in a report on Thursday, November 3rd. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $5.40.
ChromaDex Stock Performance
The firm has a market cap of $141.12 million, a price-to-earnings ratio of -6.53 and a beta of 1.66. The business’s 50-day moving average is $1.72 and its 200-day moving average is $1.63.
Institutional Investors Weigh In On ChromaDex
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Gabelli Funds LLC acquired a new stake in ChromaDex in the 3rd quarter valued at about $34,000. Oppenheimer & Co. Inc. increased its position in ChromaDex by 127.3% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 39,110 shares of the company’s stock valued at $65,000 after acquiring an additional 21,900 shares in the last quarter. Virtu Financial LLC acquired a new stake in ChromaDex in the 2nd quarter valued at about $76,000. XTX Topco Ltd acquired a new stake in ChromaDex in the 1st quarter valued at about $76,000. Finally, Royal Bank of Canada bought a new position in shares of ChromaDex in the 3rd quarter valued at about $93,000. Institutional investors and hedge funds own 42.81% of the company’s stock.
ChromaDex Company Profile
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- 3 Retail Stocks Ringing the Register in 2023
- Is It Time To Get Aggressive With Defense Stocks?
- When Will Crane Holdings Take Flight?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.